Novavax, Inc.
NVAX
$5.95
-$0.24-3.88%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 666.66M | 88.31M | 84.51M | 415.48M | 93.86M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 666.66M | 88.31M | 84.51M | 415.48M | 93.86M |
| Cost of Revenue | 103.05M | 119.58M | 147.38M | 152.39M | 150.29M |
| Gross Profit | 563.60M | -31.27M | -62.87M | 263.10M | -56.43M |
| SG&A Expenses | 47.59M | 73.34M | 66.95M | 101.00M | 82.30M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 150.64M | 213.79M | 214.33M | 253.39M | 232.59M |
| Operating Income | 516.01M | -125.48M | -129.82M | 162.10M | -138.73M |
| Income Before Tax | 519.85M | -73.58M | -122.33M | 164.59M | -145.29M |
| Income Tax Expenses | 1.20M | 7.45M | -1.03M | 2.21M | 2.26M |
| Earnings from Continuing Operations | 518.65M | -81.03M | -121.30M | 162.38M | -147.55M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 518.65M | -81.03M | -121.30M | 162.38M | -147.55M |
| EBIT | 516.01M | -125.48M | -129.82M | 162.10M | -138.73M |
| EBITDA | 524.35M | -112.96M | -117.12M | 173.23M | -126.58M |
| EPS Basic | 3.22 | -0.51 | -0.76 | 1.09 | -1.05 |
| Normalized Basic EPS | 2.02 | -0.47 | -0.46 | 0.70 | -0.62 |
| EPS Diluted | 2.93 | -0.51 | -0.76 | 0.99 | -1.05 |
| Normalized Diluted EPS | 1.83 | -0.47 | -0.46 | 0.62 | -0.62 |
| Average Basic Shares Outstanding | 161.05M | 160.24M | 160.05M | 148.38M | 139.92M |
| Average Diluted Shares Outstanding | 177.63M | 160.24M | 160.05M | 165.86M | 139.92M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |